NCT02217475

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 289 (actual)
• Sponsor: Tobira Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether cenicriviroc is effective and safe in the treatment of nonalcoholic steatohepatitis (NASH) in adult participants with liver fibrosis.

Conditions

• Nonalcoholic Steatohepatitis

Interventions

Type	Name	Description
DRUG	Cenicriviroc	CVC 150 mg, administered orally once daily and taken every morning with food.
DRUG	Placebo	Placebo administered orally once daily and taken every morning with food.

Timeline

• Start date: 2014-09-18
• Primary completion: 2016-06-30
• Completion: 2017-06-22
• First posted: 2014-08-15
• Last updated: 2019-05-10
• Results posted: 2019-05-10

Locations

91 sites across 10 countries: United States, Australia, Belgium, France, Germany, Hong Kong, Italy, Poland, Spain, United Kingdom

Regulatory

• FDA-regulated drug study